Abstract: A pharmaceutical composition is provided comprising inner ester ganglioside derivatives useful for its peripheral analgesic-antiinflammatory activity in treating pain caused by pathologies of the peripheral nervous system and which can advantageously be administered orally.
Abstract: The invention concerns the esters of hyaluronic acid in which all or only a portion of the carboxylic groups of the acid are esterified, and the salts of the partial esters with metals or with pharmacologically acceptable organic bases.The compounds possess interesting and precious bioplastic and pharmaceutical properties and may be used in innumerable fields, including cosmetics, surgery and medicine. The invention also includes pharmaceutical preparations containing, as an active ingredient, one or more hyaluronic acid esters, or a salt thereof as described above, as well as medicaments containing:(1) a pharmacologically active substance or an association of pharmacologically active substances and(2) a carrying vehicle containing a total or partial ester of hyaluronic acid.The invention includes also various uses of the hyaluronic esters or of the above mentioned medicaments, such as in medicine, surgery or cosmetics.
Abstract: Cross-linked esters of hyaluronic acid are provided which result from the esterification of polyhydric alcohols with two or more carboxy groups of the hyaluronic acid polysaccharide. These cross-linked esters are useful in the field of biodegradable plastics for sanitary and surgical articles and in the pharmaceutical and cosmetic fields for the preparation of useful compositions and articles.
Abstract: A pharmaceutical preparation containing the ganglio-side GM.sub.1 or an inner ester derivative thereof and a method for increasing cerebral blood flow in stroke victims by acute administration of GM.sub.1 or its inner ester derivative.
Type:
Grant
Filed:
October 20, 1988
Date of Patent:
July 10, 1990
Assignee:
Fidia, S.p.A.
Inventors:
Francesco della Valle, Aurelio Romeo, Silvana Lorenzi
Abstract: Organic amide compounds of the formula ##STR1## wherein R.sub.1 --CO is a residue of a carboxylic acid with the proviso that the carboxylic acid is not a natural fatty acid normally bound to nitrogen of nitrogenous lipids, R.sub.2 is a hydrogen atom, a C.sub.1-7 alkyl group, or a C.sub.4-7 cycloalkyl group, and R.sub.3-N is a residue of a nitrogenous lipid. The compounds are useful in increasing or stimulating the in vivo biological activity of in vitro biologically active carboxylic acids.
Abstract: Organic amide compounds of the formula ##STR1## wherein R.sub.1 --CO is a residue of a carboxylic acid with the proviso that the carboxylic acid is not a natural fatty acid normally bound to nitrogen of nitrogenous lipids, R.sub.2 is a hydrogen atom, a C.sub.1-7 alkyl group, or a C.sub.4-7 cycloalkyl group, and R.sub.3-N is a residue of a nitrogenous lipid. The compounds are useful in increasing or stimulating the in vivo biological activity of in vitro biologically active carboxylic acids.
Abstract: The invention concerns the esters of hyaluronic acid in which all or only a portion of the carboxylic groups of the acid are esterfied, and the salts of the partial esters with metals or with pharmacologically acceptable organic bases.The compounds possess interesting and precious bioplastic and pharmaceutical properties and may be used in innumerable fields, including cosmetics, surgery and medicine. The invention also includes pharmaceutical preparations containing, as an active ingredient, one or more hyaluronic acid esters, or a salt thereof as described above, as well as medicaments containing:(1) a pharmacologically active substance or an association of pharmacologically active substances and(2) a carrying vehicle containing a total or partial ester of hyaluronic acid. The invention includes also various uses of the hyaluronic esters or of the above mentioned medicaments, such as in medicine, surgery or cosmetics.
Abstract: New functional ganglioside derivatives comprising ester, amide and peracylated derivatives of gangliosides, preparation procedures therefor, pharmaceutical preparations containing the same, and the therapeutic use of the derivatives.
Abstract: Organic amide compounds of the formula ##STR1## wherein R.sub.1 --CO is a residue of a carboxylic acid with the proviso that the carboxylic acid is not a natural fatty acid normally bound to nitrogen of nitrogenous lipids, R.sub.2 is a hydrogen atom, a C.sub.1-7 alkyl group, or a C.sub.4-7 cycloalkyl group, and R.sub.3-N is a residue of a nitrogenous lipid. The compounds are useful in increasing or stimulating the in vivo biological activity of in vitro biologically active carboxylic acids.
Abstract: A compound having the formula: ##STR1## wherein R.sub.1 is halogen or a substituted or unsubstituted hydrocarbon group; R.sub.2 R.sub.6 and R.sub.7, which may be the same or different, each represents hydrogen or a substituted or unsubstituted hydrocarbon group, or R.sub.6 and R.sub.7 taken together may represent a hetero group having one or more hetero atoms; R.sub.3 and R.sub.4 which may be the same or different each represents a substituted or unsubstituted hydrocarbon group; or R.sub.3 and R.sub.4 taken together may represent an alkylene group or a hetero group having one or more hetero atoms and R.sub.5 is hydrogen, a substituted or unsubstituted hydrocarbon group, halogen or a free or protected hydroxy group, or a pharmaceutically acceptable salt thereof. The compounds have antiaggregating properties.
Abstract: Pharmaceutical preparations for topical administration containing a pharmacologically active substance together with hyaluronic acid or a molecular weight fraction thereof. The hyaluronic acid may be in the form of the free acid or may be a salt with an alkali or alkaline earth metal, magnesium, aluminum or ammonium, or in the form of a salt with one or more pharmacologically active substances.
Type:
Grant
Filed:
April 3, 1986
Date of Patent:
April 5, 1988
Assignee:
Fidia, S.p.A.
Inventors:
Francesco Della Valle, Aurelio Romeo, Silvana Lorenzi
Abstract: The present invention relates to a method for preparing inner ester derivatives of gangliosides and pharmaceutical compositions containing such derivatives to be used in treating disorders of the nervous system. The pharmaceutical compositions of the present invention promote nerve regeneration by stimulating nerve sprouting.
Abstract: New functional ganglioside derivatives comprising ester, amide and peracylated derivatives of gangliosides, preparation procedures therefor, pharmaceutical preparations containing the same, and the therapeutic use of the derivatives.
Abstract: A ganglioside mixture, comprised of the gangliosides GM.sub.1, GD.sub.1a, GD.sub.1b and GT.sub.1b, has been found to possess significant analgesic or pain relieving activity. The mixture is, therefore, useful for treating pain due to various peripheral neuropathies and the mixture is more effective than the individual gangliosides which comprise the mixture.
Type:
Grant
Filed:
June 13, 1985
Date of Patent:
November 17, 1987
Assignee:
Fidia, S.p.A.
Inventors:
Francesco della Valle, Aurelio Romeo, Silvana Lorenzi
Abstract: A method for the preparation of 2-halogenoresorcinols having the following formula I ##STR1## where X represents a halogen atom and R and R.sub.1 may be the same or different and represent a hydrogen atom or a free organic functional or functionally modified group or a hydrocarbon group, which may be substituted by one or more free organic functional or functionally modified groups and R and R.sub.1 jointly may also represent a free organic functional or functionally modified group or a hydrocarbon group which may be substituted by one or more free organic functional or functionally modified groups, and esters, ethers, or salts thereof.The method comprises sulfonating the corresponding resorcinols which do not contain a halogen in the 2-position and then halogenating the sulfonic acids thus obtained. The halogenated sulfonic acids thereby obtained are subsequently protodesulfonated by acid hydrolysis and, if desired, any functional groups which may be present can be modified.
Abstract: The present invention relates to a device or kit and a method for the inhalation administration of gangliosides and inner ester ganglioside derivatives useful for the treatment of various nervous disorders, such as those resulting from accidents or diseases which have damaged the nervous tissue.
Abstract: A phospholipid composition comprised of a mixture of phosphatidylserine and phosphatidylethanolamine in a specified ratio having activity against disorders of the central nervous system but without secondary haematic coagulation effects. Particularly useful compositions comprise from 60 to 75% by weight of phosphatidylserine and from 40 to 25% by weight of phosphatidylethanolamine.
Abstract: The present invention relates to a method for preparing inner ester derivatives of gangliosides and pharmaceutical compositions containing such derivatives to be used in treating disorders of the nervous system. The pharmaceutical compositions of the present invention promote nerve regeneration by stimulating nerve sprouting.
Abstract: The present invention relates to a method for preparing inner ester derivatives of gangliosides and pharmaceutical compositions containing such derivatives to be used in treating disorders of the nervous system. The pharmaceutical compositions of the present invention promote nerve regeneration by stimulating nerve sprouting.
Abstract: A selective process is described for producing monohalogenated derivatives of 7-hydroxy coumarin wherein the halo substituent is at the desired position and the final product is free of other monohalogenated isomers. The resulting products and pharmaceutical compositions containing the same, especially those wherein the halo substituent is at the 8 position, have valuable specific coronary vasodilating activity.